Pharmacokinetics in children

The pharmacokinetics and steady-state concentrations of upadacitinib are comparable in adults and adolescents aged 12 to 17 years with atopic dermatitis [SmPC Rinvoq].

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

The safety profile of upadacitinib at a dose of 15 mg/day in adolescents was similar to that in adults, although the rates of some adverse events, including neutropenia and herpes zoster, were higher in a dose-dependent manner [SmPC Rinvoq].

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Reference

1. AbbVie Deutschland GmbH & Co. KG, SmPC Rinvoq (EU/1/19/1404/009) Rev 20, www.ema.europa.eu, 24-07-2027

Changes

Therapeutic Drug Monitoring

Overdose